Solara Active Pharma Sciences Limited - Asset Resilience Ratio
Solara Active Pharma Sciences Limited (SOLARA) has an Asset Resilience Ratio of 0.74% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SOLARA current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Solara Active Pharma Sciences Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Solara Active Pharma Sciences Limited's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Solara Active Pharma Sciences Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Solara Active Pharma Sciences Limited long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs37.10 Million | 0.16% |
| Short-term Investments | Rs132.20 Million | 0.58% |
| Total Liquid Assets | Rs169.30 Million | 0.74% |
Asset Resilience Insights
- Limited Liquidity: Solara Active Pharma Sciences Limited maintains only 0.74% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Solara Active Pharma Sciences Limited Industry Peers by Asset Resilience Ratio
Compare Solara Active Pharma Sciences Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Solara Active Pharma Sciences Limited (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Solara Active Pharma Sciences Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.74% | Rs164.70 Million ≈ $1.78 Million |
Rs22.32 Billion ≈ $241.37 Million |
+0.42pp |
| 2024-03-31 | 0.32% | Rs75.80 Million ≈ $819.75K |
Rs23.51 Billion ≈ $254.25 Million |
-0.44pp |
| 2023-03-31 | 0.76% | Rs221.20 Million ≈ $2.39 Million |
Rs28.99 Billion ≈ $313.52 Million |
-1.03pp |
| 2022-03-31 | 1.79% | Rs528.70 Million ≈ $5.72 Million |
Rs29.53 Billion ≈ $319.30 Million |
-6.74pp |
| 2021-03-31 | 8.54% | Rs2.23 Billion ≈ $24.13 Million |
Rs26.14 Billion ≈ $282.65 Million |
+5.28pp |
| 2020-03-31 | 3.25% | Rs700.50 Million ≈ $7.58 Million |
Rs21.54 Billion ≈ $232.89 Million |
+3.12pp |
| 2019-03-31 | 0.13% | Rs25.98 Million ≈ $280.96K |
Rs19.60 Billion ≈ $211.97 Million |
+0.34pp |
| 2018-03-31 | -0.21% | Rs-38.17 Million ≈ $-412.79K |
Rs18.22 Billion ≈ $196.99 Million |
-- |
About Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arr… Read more